Employees: 3,108
Size Solara Active Pharma Sciences (SOLARA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $334M, the 1021st largest of 1,066 India companies the cockpit tracks. Shares closed at ₹650.50 on 18 Nov 2026.
Performance Over six months the shares gained 11.7%, against -18.6% for the median peer and +3.8% for the India market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 27.3% over the last twelve months (peer median +2.7%); the operating margin is 8.4% (peer median 2.3%).
Valuation It trades at 20.7× forward earnings against a peer median of 24.9× (3rd cheapest of 6).
Price implies For today's price to make sense, revenue must grow about 38% a year for seven years (Req g). Recent delivered growth is -3%, so the hurdle is +42 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 11.6 points below its cost of capital (16.5% WACC).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹15.4B | ₹13.6B | ₹12.7B | ₹12.7B | ₹14.3B |
| Revenue growth | — | +7% | 0% | -11% | — |
| Gross profit | ₹4.12B | ₹1.94B | ₹1.86B | -₹1.30B | ₹1.25B |
| EBITDA | ₹2.34B | ₹1.80B | ₹1.93B | -₹2.83B | ₹1.19B |
| Net income | ₹369M | -₹74.1M | ₹5.40M | -₹5.67B | -₹222M |
| Free cash flow | n/a | ₹88.8M | ₹605M | -₹316M | -₹352M |
| Capital expenditure | n/a | ₹528M | ₹399M | ₹411M | ₹1.11B |
| Total debt | ₹5.91B | ₹6.87B | ₹7.96B | ₹10.1B | ₹10.1B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SOLARA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.8% | -6.4% | 5th highest of 21 |
| 6-month return | +11.7% | -18.6% | 6th highest of 21 |
| Distance from 52-week high | -16.0% | -34.9% | 4th highest of 21 |
| Revenue growth (TTM) | +27.3% | +2.7% | 3rd highest of 20 |
| Operating margin | 8.4% | 2.3% | 5th highest of 19 |
| Forward P/E | 20.7× | 24.9× | 3rd cheapest of 6 |
| Growth the price implies (Req g, 7 yrs) | 38.3% | 8.0% | 2nd most demanding of 12 |
| Growth delivered (Del g) | -3.2% | +4.2% | 4th lowest of 12 |
| Hurdle (Req g minus delivered) | +41.5 pp | +2.8 pp | most demanding of 12 |
| ROIC minus cost of capital | -11.6 pp | -7.1 pp | 7th lowest of 18 |
| EV / EBITDA | 15.6× | 12.6× | 5th cheapest of 9 |
| Net debt / EBITDA | 2.2× | -0.6× | 3rd most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Solara Active Pharma Sciences SOLARA.NS | India | $334M | +12% | +27% | 8% | 20.7× | 38.3% | -3.2% |
| BioDlink International 1875.HK | Hong Kong | $334M | -24% | -51% | -31% | 288.2× | n/a | n/a |
| Mayne Pharma MYX.AX | Australia | $333M | +155% | -6% | -14% | n/a | 19.0% | -0.9% |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $333M | -28% | +3% | 6% | n/a | 9.2% | +6.5% |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | -1% | +5% | 22% | n/a | -11.5% | +10.3% |
| Chongqing Hifuture Information Technology 002168.SZ | China | $326M | -27% | +2% | -6% | n/a | 14.3% | -14.0% |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $326M | -39% | +10% | -8% | n/a | n/a | n/a |
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $322M | -12% | +6% | -104% | n/a | n/a | n/a |
| Swedencare SECARE.ST | Sweden | $321M | -24% | +3% | 7% | 24.9× | 6.1% | +62.1% |
| GC Corp. 005250.KS | South Korea | $321M | -45% | +2% | 3% | n/a | n/a | n/a |
| Atea Pharmaceuticals AVIR | United States | $320M | -5% | n/a | n/a | n/a | n/a | n/a |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $351M | -23% | -26% | -15% | n/a | 8.0% | -11.3% |
| Kitazato 368A.T | Japan | $317M | +7% | +9% | 52% | 12.2× | -16.8% | +5.4% |
| Inovio Pharmaceuticals INO | United States | $317M | +37% | +64% | -25,954% | n/a | n/a | n/a |
| ASKA Pharmaceutical 4886.T | Japan | $354M | -24% | +11% | n/a | 12.9× | n/a | n/a |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $355M | -17% | -24% | 3% | n/a | 3.6% | +3.1% |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $314M | +150% | +66% | 9% | n/a | n/a | n/a |
| Chengdu Huasun Technology 000790.SZ | China | $312M | -20% | -36% | -57% | n/a | 27.5% | -6.4% |
| KYORIN Pharmaceutical 4569.T | Japan | $360M | -22% | -6% | 2% | 35.5× | 6.7% | +4.2% |
| Unichem Laboratories UNICHEMLAB.NS | India | $361M | +28% | +6% | 5% | n/a | n/a | n/a |
| Alembic ALEMBICLTD.NS | India | $309M | +25% | -5% | 26% | n/a | 44.3% | +26.7% |